Heparin Conjugate Pretreatment of Kidneys From Deceased Donors Before Transplantation: Results From the First-in-human Randomized Phase I Trial

• Published in: Transplantation direct Vol. 9; no. 1; p. e1403
• Main Authors: Sedigh, Amir, Lundgren, Torbjörn, Lindnér, Per, Nordström, Johan, Magnusson, Peetra, Jönsson, Janniz, Carlsson, Fredrik, Ploeg, Rutger, Lorant, Tomas
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-01-2023; Wolters Kluwer
• Subjects: Kidney Transplantation; Kirurgi; Medicin och hälsovetenskap; Surgery
• ISSN: 2373-8731; 2373-8731
• DOI: 10.1097/TXD.0000000000001403

Pretreating porcine kidneys with Corline Heparin Conjugate (CHC) during hypothermic machine perfusion (HMP) has been shown to reduce preservation injury and improve early kidney function. In this first-in-human phase I study, the safety and tolerability of transplanting CHC-pretreated kidneys were evaluated.
CHC or placebo was added to the preservation solution during HMP of donated kidneys from deceased donors for at least 3 h before transplantation into adult patients. The primary safety endpoint was the number and severity of adverse events (AEs) and serious AEs (SAEs) during the first 30 d after transplantation.
In the first 30 d, 66 AEs were reported in 8 patients who received CHC-pretreated kidneys with 39 AEs in 8 patients who received placebo-pretreated kidneys (
 = 0.1 in post hoc analysis). The most common AEs were hypertension (CHC, n = 5; placebo, n = 2) and anemia (CHC, n = 5; placebo, n = 2). Most AEs were assessed as mild (58%) or moderate (39%) and not related to treatment (95%). There were 2 SAEs reported in each group. One SAE, considered possibly related to CHC treatment, was a case of severe postprocedural hemorrhage that required reoperation. No patients needed dialysis. There were no observed rejections and no patient deaths.
Pretreatment of kidneys with CHC before transplantation was considered safe and tolerable. Efficacy studies are now planned to investigate if CHC can reduce early ischemia-reperfusion injury in humans.